(Q53338908)

13 May 2018

title

International study comparing cefdinir and cefuroxime axetil in the treatment of patients with acute exacerbation of chronic bronchitis. (English)

1 reference

13 May 2018

1 reference

Van Herwaarden CL

1

1 reference

13 May 2018

Langan CE

2

1 reference

13 May 2018

Siemon G

3

1 reference

13 May 2018

Rudolph C

4

1 reference

13 May 2018

Keyserling CH

5

1 reference

13 May 2018

Nemeth MA

6

1 reference

13 May 2018

Tack KJ

7

1 reference

13 May 2018

publication date

1 January 2000

1 reference

13 May 2018

International Journal of Infectious Diseases

published in

1 reference

13 May 2018

volume

4

1 reference

13 May 2018

issue

1

1 reference

13 May 2018

page(s)

26-33

1 reference

13 May 2018

Cefpodoxime Proxetil in the Treatment of Lower Respiratory Tract Infections

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2800%2990062-6

7 January 2021

Review of the Experience with Cefprozil for the Treatment of Lower Respiratory Tract Infections

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2800%2990062-6

7 January 2021

Incidence of beta-lactamase production among out patient clinical isolates in Middle Eastern countries and their antibiotic susceptibilities. Middle Eastern Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2800%2990062-6

7 January 2021

Antimicrobial susceptibility of bacterial isolates in south Sweden including a 13-year follow-up study of some respiratory tract pathogens.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2800%2990062-6

7 January 2021

Stability in the presence of widespread beta-lactamases. A prerequisite for the antibacterial activity of beta-lactam drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2800%2990062-6

7 January 2021

In vitro evaluation of cefdinir (FK482), a new oral cephalosporin with enhanced antistaphylococcal activity and beta-lactamase stability.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2800%2990062-6

7 January 2021

In vitro antibacterial activity of FK482, a new orally active cephalosporin

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2800%2990062-6

7 January 2021

Interlaboratory variations of fluoroquinolone susceptibility testing. An international study to validate the quality of microbiology results reported during the fleroxacin clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2800%2990062-6

7 January 2021

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2800%2990062-6

7 January 2021

Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2800%2990062-6

7 January 2021

Cefuroxime and cefuroxime axetil versus amoxicillin plus clavulanic acid in the treatment of lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2800%2990062-6

7 January 2021

Literature survey on clinical efficacy and tolerability on cefetamet pivoxil: an analysis of 3,128 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2800%2990062-6

7 January 2021

10.1016/S1201-9712(00)90062-6

Identifiers

DOI

1 reference

13 May 2018

1 reference

13 May 2018